Immix Biopharma Inc

NASDAQ IMMX

Download Data

Immix Biopharma Inc Working Capital to Current Liabilities Ratio 2 year CAGR for the year ending December 31, 2023: -77.98%

Immix Biopharma Inc Working Capital to Current Liabilities Ratio 2 year CAGR is -77.98% for the year ending December 31, 2023. The working capital to current liabilities ratio measures the proportion of working capital to current liabilities. It is calculated by dividing the difference between current assets and current liabilities by current liabilities. This ratio indicates the company's ability to cover its current liabilities with its working capital. A higher ratio suggests a healthier liquidity position and better ability to meet short-term obligations. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Immix Biopharma Inc Working Capital to Current Liabilities Ratio for the year ending December 31, 2022 was 10.70, a -87.98% change year over year.
  • Immix Biopharma Inc Working Capital to Current Liabilities Ratio for the year ending December 31, 2021 was 89.01, a 10,001.37% change year over year.
  • Immix Biopharma Inc Working Capital to Current Liabilities Ratio for the year ending December 31, 2020 was -0.90, a -12.85% change year over year.
  • Immix Biopharma Inc Working Capital to Current Liabilities Ratio for the year ending December 31, 2019 was -0.80.
NASDAQ: IMMX

Immix Biopharma Inc

CEO Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
IPO Date Dec. 16, 2021
Location United States
Headquarters 11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064
Employees 14
Sector Healthcare
Industry Biotechnology
Description

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Similar companies

HEPA

Hepion Pharmaceuticals Inc

NA

NA

AVRO

AVROBIO Inc

NA

NA

FRLN

Freeline Therapeutics Holdings Plc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email